Survival analysis in high-grade glioma: the role of salvage surgery

No Thumbnail Available

Date

2022-12-22

Authors

Lopez, A. J. Vargas
Carballal, C. Fernandez
Mele, M. Valera
Rodriguez-Boto, G.

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier espana slu
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Objectives: This study addresses the survival of consecutive patients with high-grade gliomas treated at the same institution over a period of 10 years. We analyse the importance of associated factors and the role of salvage surgery at the time of progression.Methods: We retrospectively analysed a series of patients with World Health Organization (WHO) grade III/IV gliomas treated between 2008 and 2017 at Hospital Gregorio Maranon (Madrid, Spain). Clinical, radiological, and anatomical pathology data were obtained from patient clinical histories.Results: Follow-up was completed in 233 patients with HGG. Mean age was 62.2 years. The median survival time was 15.4 months. Of 133 patients (59.6%) who had undergone surgery at the time of diagnosis, 43 (32.3%) underwent salvage surgery at the time of progression. This subgroup presented longer overall survival and survival after progression. Higher Karnofsky Performance Status score at diagnosis, a greater extent of surgical resection, and initial diagnosis of WHO grade III glioma were also associated with longer survival.Conclusions: About one-third of patients with HGG may be eligible for salvage surgery at the time of progression. Salvage surgery in this subgroup of patients was significantly associated with longer survival. (c) 2020 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Description

MeSH Terms

DeCS Terms

CIE Terms

Keywords

High-grade glioma, Recurrence, Extent of resection, Reoperation, Salvage surgery, Survival, Recurrent glioblastoma, 2nd surgery, Resection, Reoperation, Reirradiation, Multicenter, Bevacizumab, Radiotherapy, Temozolomide, Organization

Citation